AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENTDevelopment and Commercialization License Agreement • July 31st, 2020 • Opko Health, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 31st, 2020 Company Industry JurisdictionThis Amended and Restated Development and Commercialization License Agreement (the “Agreement”) is entered into as of May 12, 2020 (the “Amendment Execution Date”) and is made effective as of January 1, 2020 (the “Amendment Effective Date”), by and between Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and OPKO Ireland Ltd., an entity organized and existing under the laws of Ireland (“OPKO”). Pfizer and OPKO are referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • July 31st, 2020 • Opko Health, Inc. • Pharmaceutical preparations
Contract Type FiledJuly 31st, 2020 Company IndustryAMENDMENT AGREEMENT to Development and License Agreement effective as of 8 May 2016 (“the Agreement”) between EirGen Pharma Limited, West Side Business, Old Kilmeaden, Waterford, Ireland (“OPKO”) on the one part and Vifor Fresenius Medical Care Renal Pharma Ltd, Rechenstrasse 37, 9014 St. Gallen, Switzerland (“VF”) on the other part.